Alivus Life Sciences Ltd reports Q2 FY27 net profit of ₹196.7 crore, up 51.3% YoY
- Revenue was ₹682 crore, up 16.0% YoY and 6.5% QoQ.
- EBITDA margin was 38.9%, versus 33.1% in Q1 FY27 and 30.5% in Q2 FY26.
- No exceptional items were reported; the auditor issued an unmodified limited-review conclusion. The Board approved the results on October 29, 2026.